RxDoctor Payments Data

Samuel Sultan, MD

Transplant Surgery · Hackensack, NJNPI 1497997837

Payments from drug & device makers

What this record shows

This record is dominated by education: $1,669 of the $2,674 with a category attached, or 62.4%. Intuitive Surgical accounts for 74.8% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $2,301, more than ten times the $142 reported in 2019.

$2,674in general payments, 2019–2025

Across 16 payments — averaging $167.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • AstraZeneca$254
  • Sanofi$121
  • Sanofi-aventis U.S. LLC$117
  • ZOLL Medical Corporation$115
  • Kerecis Limited$28
  • plus $39 from 2 others

What the payments were for

  • Consulting fees$1154%
  • Travel & lodging$48318%
  • Food & beverage$40615%
  • Education$1,66962%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few transplant surgery providers in New Jerseyto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$177,949
Medicare patients
112
Services billed
370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Envarsus XrTacrolimus14$18,920
Valganciclovir Hcl133$18,019
LokelmaSodium Zirconium Cyclosilicate11$6,493
Mycophenolic AcidMycophenolate Sodium31$5,377
Nifedipine ErNifedipine136$1,882
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim265$1,700
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$1,512
Nano 2nd Gen Pen NeedlePen Needle, Diabetic20$1,322
Labetalol Hcl43$1,309
Ultra-Fine Nano Pen NeedlePen Needle, Diabetic20$1,115
Nystatin30$1,072
Pantoprazole Sodium72$669
Tamsulosin Hcl68$576
Entecavir11$572
Prednisone123$530

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$254$6,49311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few transplant surgery providers in New Jerseyon file to place this against a meaningful peer group, so we don't.

Other transplant surgery in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →